0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cardiovascular Drugs Market Insights, Forecast to 2029
Published Date: August 2023
|
Report Code: QYRE-Auto-8U8905
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
China Cardiovascular Drugs Market Report Forecast 2021 2027
BUY CHAPTERS

Global Cardiovascular Drugs Market Insights, Forecast to 2029

Code: QYRE-Auto-8U8905
Report
August 2023
Pages:106
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cardiovascular Drugs Market Size

The global Cardiovascular Drugs market is projected to grow from US$ 6066.5 million in 2023 to US$ 6361.2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 0.8% during the forecast period.

Cardiovascular Drugs Market

Cardiovascular Drugs Market

Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).
Geographically, North America captured lion’s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.

Report Includes:

This report presents an overview of global market for Cardiovascular Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Cardiovascular Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Cardiovascular Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cardiovascular Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Cardiovascular Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Cardiovascular Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amgen, AstraZeneca, Bayer, Bristol Myers Squibb and Pfizer, Daiichi Sankyo, Johnson & Johnson, Merck & Co., Novartis and Pfizer, etc.

Scope of Cardiovascular Drugs Market Report

Report Metric Details
Report Name Cardiovascular Drugs Market
Accounted market size in 2023 US$ 6066.5 million
Forecasted market size in 2029 US$ 6361.2 million
CAGR 0.8
Base Year 2023
Forecasted years 2023 - 2029
Segment by Type
  • Renin-Angiotensin System Blockers
  • Beta Blockers
  • Diuretics
  • Anti-Clotting Agents
  • Antihyperlipidemic
Segment by Application
  • Hypertension
  • Hyperlipidemia
Segment by Region
  • US & Canada
  • U.S.
  • Canada
  • China
  • Asia (excluding China)
  • Japan
  • South Korea
  • China Taiwan
  • Southeast Asia
  • India
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Middle East, Africa, Latin America
  • Brazil
  • Mexico
  • Turkey
  • Israel
  • GCC Countries
By Company Amgen, AstraZeneca, Bayer, Bristol Myers Squibb and Pfizer, Daiichi Sankyo, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Portola, Sanofi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Cardiovascular Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 3: Detailed analysis of Cardiovascular Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
  • Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
  • Chapter 8: China by type, by application sales and revenue for each segment.
  • Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
  • Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cardiovascular Drugs sales, revenue, price, gross margin, and recent development, etc.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: The main points and conclusions of the report.

FAQ for this report

How fast is Cardiovascular Drugs Market growing?

Ans: The Cardiovascular Drugs Market witnessing a CAGR of 0.8 during the forecast period 2023-2029.

What is the Cardiovascular Drugs Market size in 2029?

Ans: The global Cardiovascular Drugs market is projected to grow from US$ 6066.5 million in 2023 to US$ 6361.2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 0.8% during the forecast period.

1 Study Coverage
1.1 Cardiovascular Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Cardiovascular Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Renin-Angiotensin System Blockers
1.2.3 Beta Blockers
1.2.4 Diuretics
1.2.5 Anti-Clotting Agents
1.2.6 Antihyperlipidemic
1.3 Market by Application
1.3.1 Global Cardiovascular Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hypertension
1.3.3 Hyperlipidemia
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cardiovascular Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Cardiovascular Drugs Revenue by Region
2.2.1 Global Cardiovascular Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Cardiovascular Drugs Revenue by Region (2018-2023)
2.2.3 Global Cardiovascular Drugs Revenue by Region (2024-2029)
2.2.4 Global Cardiovascular Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Cardiovascular Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Cardiovascular Drugs Sales by Region
2.4.1 Global Cardiovascular Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Cardiovascular Drugs Sales by Region (2018-2023)
2.4.3 Global Cardiovascular Drugs Sales by Region (2024-2029)
2.4.4 Global Cardiovascular Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Cardiovascular Drugs Sales by Manufacturers
3.1.1 Global Cardiovascular Drugs Sales by Manufacturers (2018-2023)
3.1.2 Global Cardiovascular Drugs Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cardiovascular Drugs in 2022
3.2 Global Cardiovascular Drugs Revenue by Manufacturers
3.2.1 Global Cardiovascular Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Cardiovascular Drugs Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Cardiovascular Drugs Revenue in 2022
3.3 Global Key Players of Cardiovascular Drugs, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Cardiovascular Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Cardiovascular Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Cardiovascular Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Cardiovascular Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Cardiovascular Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cardiovascular Drugs Sales by Type
4.1.1 Global Cardiovascular Drugs Historical Sales by Type (2018-2023)
4.1.2 Global Cardiovascular Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Cardiovascular Drugs Sales Market Share by Type (2018-2029)
4.2 Global Cardiovascular Drugs Revenue by Type
4.2.1 Global Cardiovascular Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Cardiovascular Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Cardiovascular Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Cardiovascular Drugs Price by Type
4.3.1 Global Cardiovascular Drugs Price by Type (2018-2023)
4.3.2 Global Cardiovascular Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Cardiovascular Drugs Sales by Application
5.1.1 Global Cardiovascular Drugs Historical Sales by Application (2018-2023)
5.1.2 Global Cardiovascular Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Cardiovascular Drugs Sales Market Share by Application (2018-2029)
5.2 Global Cardiovascular Drugs Revenue by Application
5.2.1 Global Cardiovascular Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Cardiovascular Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Cardiovascular Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Cardiovascular Drugs Price by Application
5.3.1 Global Cardiovascular Drugs Price by Application (2018-2023)
5.3.2 Global Cardiovascular Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Cardiovascular Drugs Market Size by Type
6.1.1 US & Canada Cardiovascular Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Cardiovascular Drugs Revenue by Type (2018-2029)
6.2 US & Canada Cardiovascular Drugs Market Size by Application
6.2.1 US & Canada Cardiovascular Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Cardiovascular Drugs Revenue by Application (2018-2029)
6.3 US & Canada Cardiovascular Drugs Market Size by Country
6.3.1 US & Canada Cardiovascular Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Cardiovascular Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Cardiovascular Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Cardiovascular Drugs Market Size by Type
7.1.1 Europe Cardiovascular Drugs Sales by Type (2018-2029)
7.1.2 Europe Cardiovascular Drugs Revenue by Type (2018-2029)
7.2 Europe Cardiovascular Drugs Market Size by Application
7.2.1 Europe Cardiovascular Drugs Sales by Application (2018-2029)
7.2.2 Europe Cardiovascular Drugs Revenue by Application (2018-2029)
7.3 Europe Cardiovascular Drugs Market Size by Country
7.3.1 Europe Cardiovascular Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Cardiovascular Drugs Sales by Country (2018-2029)
7.3.3 Europe Cardiovascular Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Cardiovascular Drugs Market Size
8.1.1 China Cardiovascular Drugs Sales (2018-2029)
8.1.2 China Cardiovascular Drugs Revenue (2018-2029)
8.2 China Cardiovascular Drugs Market Size by Application
8.2.1 China Cardiovascular Drugs Sales by Application (2018-2029)
8.2.2 China Cardiovascular Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Cardiovascular Drugs Market Size by Type
9.1.1 Asia Cardiovascular Drugs Sales by Type (2018-2029)
9.1.2 Asia Cardiovascular Drugs Revenue by Type (2018-2029)
9.2 Asia Cardiovascular Drugs Market Size by Application
9.2.1 Asia Cardiovascular Drugs Sales by Application (2018-2029)
9.2.2 Asia Cardiovascular Drugs Revenue by Application (2018-2029)
9.3 Asia Cardiovascular Drugs Sales by Region
9.3.1 Asia Cardiovascular Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Cardiovascular Drugs Revenue by Region (2018-2029)
9.3.3 Asia Cardiovascular Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Cardiovascular Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Cardiovascular Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Cardiovascular Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Cardiovascular Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Cardiovascular Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Cardiovascular Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Amgen Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 AstraZeneca Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Bayer
11.3.1 Bayer Company Information
11.3.2 Bayer Overview
11.3.3 Bayer Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Bayer Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bayer Recent Developments
11.4 Bristol Myers Squibb and Pfizer
11.4.1 Bristol Myers Squibb and Pfizer Company Information
11.4.2 Bristol Myers Squibb and Pfizer Overview
11.4.3 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bristol Myers Squibb and Pfizer Recent Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Information
11.5.2 Daiichi Sankyo Overview
11.5.3 Daiichi Sankyo Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Daiichi Sankyo Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Daiichi Sankyo Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Information
11.6.2 Johnson & Johnson Overview
11.6.3 Johnson & Johnson Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Johnson & Johnson Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Johnson & Johnson Recent Developments
11.7 Merck & Co.
11.7.1 Merck & Co. Company Information
11.7.2 Merck & Co. Overview
11.7.3 Merck & Co. Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Merck & Co. Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Merck & Co. Recent Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Overview
11.8.3 Novartis Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Novartis Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novartis Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Overview
11.9.3 Pfizer Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Pfizer Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Pfizer Recent Developments
11.10 Portola
11.10.1 Portola Company Information
11.10.2 Portola Overview
11.10.3 Portola Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Portola Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Portola Recent Developments
11.11 Sanofi
11.11.1 Sanofi Company Information
11.11.2 Sanofi Overview
11.11.3 Sanofi Cardiovascular Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Sanofi Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Sanofi Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cardiovascular Drugs Industry Chain Analysis
12.2 Cardiovascular Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cardiovascular Drugs Production Mode & Process
12.4 Cardiovascular Drugs Sales and Marketing
12.4.1 Cardiovascular Drugs Sales Channels
12.4.2 Cardiovascular Drugs Distributors
12.5 Cardiovascular Drugs Customers
13 Market Dynamics
13.1 Cardiovascular Drugs Industry Trends
13.2 Cardiovascular Drugs Market Drivers
13.3 Cardiovascular Drugs Market Challenges
13.4 Cardiovascular Drugs Market Restraints
14 Key Findings in The Global Cardiovascular Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Cardiovascular Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Table 2. Major Manufacturers of Renin-Angiotensin System Blockers
    Table 3. Major Manufacturers of Beta Blockers
    Table 4. Major Manufacturers of Diuretics
    Table 5. Major Manufacturers of Anti-Clotting Agents
    Table 6. Major Manufacturers of Antihyperlipidemic
    Table 7. Global Cardiovascular Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Table 8. Global Cardiovascular Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 9. Global Cardiovascular Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 10. Global Cardiovascular Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 11. Global Cardiovascular Drugs Revenue Market Share by Region (2018-2023)
    Table 12. Global Cardiovascular Drugs Revenue Market Share by Region (2024-2029)
    Table 13. Global Cardiovascular Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 14. Global Cardiovascular Drugs Sales by Region (2018-2023) & (K Units)
    Table 15. Global Cardiovascular Drugs Sales by Region (2024-2029) & (K Units)
    Table 16. Global Cardiovascular Drugs Sales Market Share by Region (2018-2023)
    Table 17. Global Cardiovascular Drugs Sales Market Share by Region (2024-2029)
    Table 18. Global Cardiovascular Drugs Sales by Manufacturers (2018-2023) & (K Units)
    Table 19. Global Cardiovascular Drugs Sales Share by Manufacturers (2018-2023)
    Table 20. Global Cardiovascular Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
    Table 21. Global Cardiovascular Drugs Revenue Share by Manufacturers (2018-2023)
    Table 22. Global Key Players of Cardiovascular Drugs, Industry Ranking, 2021 VS 2022 VS 2023
    Table 23. Cardiovascular Drugs Price by Manufacturers 2018-2023 (USD/Unit)
    Table 24. Global Cardiovascular Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 25. Global Cardiovascular Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiovascular Drugs as of 2022)
    Table 26. Global Key Manufacturers of Cardiovascular Drugs, Manufacturing Base Distribution and Headquarters
    Table 27. Global Key Manufacturers of Cardiovascular Drugs, Product Offered and Application
    Table 28. Global Key Manufacturers of Cardiovascular Drugs, Date of Enter into This Industry
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Cardiovascular Drugs Sales by Type (2018-2023) & (K Units)
    Table 31. Global Cardiovascular Drugs Sales by Type (2024-2029) & (K Units)
    Table 32. Global Cardiovascular Drugs Sales Share by Type (2018-2023)
    Table 33. Global Cardiovascular Drugs Sales Share by Type (2024-2029)
    Table 34. Global Cardiovascular Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 35. Global Cardiovascular Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 36. Global Cardiovascular Drugs Revenue Share by Type (2018-2023)
    Table 37. Global Cardiovascular Drugs Revenue Share by Type (2024-2029)
    Table 38. Cardiovascular Drugs Price by Type (2018-2023) & (USD/Unit)
    Table 39. Global Cardiovascular Drugs Price Forecast by Type (2024-2029) & (USD/Unit)
    Table 40. Global Cardiovascular Drugs Sales by Application (2018-2023) & (K Units)
    Table 41. Global Cardiovascular Drugs Sales by Application (2024-2029) & (K Units)
    Table 42. Global Cardiovascular Drugs Sales Share by Application (2018-2023)
    Table 43. Global Cardiovascular Drugs Sales Share by Application (2024-2029)
    Table 44. Global Cardiovascular Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 45. Global Cardiovascular Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 46. Global Cardiovascular Drugs Revenue Share by Application (2018-2023)
    Table 47. Global Cardiovascular Drugs Revenue Share by Application (2024-2029)
    Table 48. Cardiovascular Drugs Price by Application (2018-2023) & (USD/Unit)
    Table 49. Global Cardiovascular Drugs Price Forecast by Application (2024-2029) & (USD/Unit)
    Table 50. US & Canada Cardiovascular Drugs Sales by Type (2018-2023) & (K Units)
    Table 51. US & Canada Cardiovascular Drugs Sales by Type (2024-2029) & (K Units)
    Table 52. US & Canada Cardiovascular Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 53. US & Canada Cardiovascular Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 54. US & Canada Cardiovascular Drugs Sales by Application (2018-2023) & (K Units)
    Table 55. US & Canada Cardiovascular Drugs Sales by Application (2024-2029) & (K Units)
    Table 56. US & Canada Cardiovascular Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 57. US & Canada Cardiovascular Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 58. US & Canada Cardiovascular Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 59. US & Canada Cardiovascular Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 60. US & Canada Cardiovascular Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 61. US & Canada Cardiovascular Drugs Sales by Country (2018-2023) & (K Units)
    Table 62. US & Canada Cardiovascular Drugs Sales by Country (2024-2029) & (K Units)
    Table 63. Europe Cardiovascular Drugs Sales by Type (2018-2023) & (K Units)
    Table 64. Europe Cardiovascular Drugs Sales by Type (2024-2029) & (K Units)
    Table 65. Europe Cardiovascular Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 66. Europe Cardiovascular Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 67. Europe Cardiovascular Drugs Sales by Application (2018-2023) & (K Units)
    Table 68. Europe Cardiovascular Drugs Sales by Application (2024-2029) & (K Units)
    Table 69. Europe Cardiovascular Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 70. Europe Cardiovascular Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 71. Europe Cardiovascular Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 72. Europe Cardiovascular Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 73. Europe Cardiovascular Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 74. Europe Cardiovascular Drugs Sales by Country (2018-2023) & (K Units)
    Table 75. Europe Cardiovascular Drugs Sales by Country (2024-2029) & (K Units)
    Table 76. China Cardiovascular Drugs Sales by Type (2018-2023) & (K Units)
    Table 77. China Cardiovascular Drugs Sales by Type (2024-2029) & (K Units)
    Table 78. China Cardiovascular Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 79. China Cardiovascular Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 80. China Cardiovascular Drugs Sales by Application (2018-2023) & (K Units)
    Table 81. China Cardiovascular Drugs Sales by Application (2024-2029) & (K Units)
    Table 82. China Cardiovascular Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 83. China Cardiovascular Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 84. Asia Cardiovascular Drugs Sales by Type (2018-2023) & (K Units)
    Table 85. Asia Cardiovascular Drugs Sales by Type (2024-2029) & (K Units)
    Table 86. Asia Cardiovascular Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 87. Asia Cardiovascular Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 88. Asia Cardiovascular Drugs Sales by Application (2018-2023) & (K Units)
    Table 89. Asia Cardiovascular Drugs Sales by Application (2024-2029) & (K Units)
    Table 90. Asia Cardiovascular Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 91. Asia Cardiovascular Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 92. Asia Cardiovascular Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 93. Asia Cardiovascular Drugs Revenue by Region (2018-2023) & (US$ Million)
    Table 94. Asia Cardiovascular Drugs Revenue by Region (2024-2029) & (US$ Million)
    Table 95. Asia Cardiovascular Drugs Sales by Region (2018-2023) & (K Units)
    Table 96. Asia Cardiovascular Drugs Sales by Region (2024-2029) & (K Units)
    Table 97. Middle East, Africa and Latin America Cardiovascular Drugs Sales by Type (2018-2023) & (K Units)
    Table 98. Middle East, Africa and Latin America Cardiovascular Drugs Sales by Type (2024-2029) & (K Units)
    Table 99. Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Type (2018-2023) & (US$ Million)
    Table 100. Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Type (2024-2029) & (US$ Million)
    Table 101. Middle East, Africa and Latin America Cardiovascular Drugs Sales by Application (2018-2023) & (K Units)
    Table 102. Middle East, Africa and Latin America Cardiovascular Drugs Sales by Application (2024-2029) & (K Units)
    Table 103. Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Application (2018-2023) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Application (2024-2029) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Cardiovascular Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 106. Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Country (2018-2023) & (US$ Million)
    Table 107. Middle East, Africa and Latin America Cardiovascular Drugs Revenue by Country (2024-2029) & (US$ Million)
    Table 108. Middle East, Africa and Latin America Cardiovascular Drugs Sales by Country (2018-2023) & (K Units)
    Table 109. Middle East, Africa and Latin America Cardiovascular Drugs Sales by Country (2024-2029) & (K Units)
    Table 110. Amgen Company Information
    Table 111. Amgen Description and Major Businesses
    Table 112. Amgen Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 113. Amgen Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Amgen Recent Developments
    Table 115. AstraZeneca Company Information
    Table 116. AstraZeneca Description and Major Businesses
    Table 117. AstraZeneca Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 118. AstraZeneca Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. AstraZeneca Recent Developments
    Table 120. Bayer Company Information
    Table 121. Bayer Description and Major Businesses
    Table 122. Bayer Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 123. Bayer Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Bayer Recent Developments
    Table 125. Bristol Myers Squibb and Pfizer Company Information
    Table 126. Bristol Myers Squibb and Pfizer Description and Major Businesses
    Table 127. Bristol Myers Squibb and Pfizer Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 128. Bristol Myers Squibb and Pfizer Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Bristol Myers Squibb and Pfizer Recent Developments
    Table 130. Daiichi Sankyo Company Information
    Table 131. Daiichi Sankyo Description and Major Businesses
    Table 132. Daiichi Sankyo Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 133. Daiichi Sankyo Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Daiichi Sankyo Recent Developments
    Table 135. Johnson & Johnson Company Information
    Table 136. Johnson & Johnson Description and Major Businesses
    Table 137. Johnson & Johnson Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 138. Johnson & Johnson Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Johnson & Johnson Recent Developments
    Table 140. Merck & Co. Company Information
    Table 141. Merck & Co. Description and Major Businesses
    Table 142. Merck & Co. Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 143. Merck & Co. Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Merck & Co. Recent Developments
    Table 145. Novartis Company Information
    Table 146. Novartis Description and Major Businesses
    Table 147. Novartis Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 148. Novartis Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Novartis Recent Developments
    Table 150. Pfizer Company Information
    Table 151. Pfizer Description and Major Businesses
    Table 152. Pfizer Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 153. Pfizer Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 154. Pfizer Recent Developments
    Table 155. Portola Company Information
    Table 156. Portola Description and Major Businesses
    Table 157. Portola Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 158. Portola Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 159. Portola Recent Developments
    Table 160. Sanofi Company Information
    Table 161. Sanofi Description and Major Businesses
    Table 162. Sanofi Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 163. Sanofi Cardiovascular Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 164. Sanofi Recent Developments
    Table 165. Key Raw Materials Lists
    Table 166. Raw Materials Key Suppliers Lists
    Table 167. Cardiovascular Drugs Distributors List
    Table 168. Cardiovascular Drugs Customers List
    Table 169. Cardiovascular Drugs Market Trends
    Table 170. Cardiovascular Drugs Market Drivers
    Table 171. Cardiovascular Drugs Market Challenges
    Table 172. Cardiovascular Drugs Market Restraints
    Table 173. Research Programs/Design for This Report
    Table 174. Key Data Information from Secondary Sources
    Table 175. Key Data Information from Primary Sources
List of Figures
    Figure 1. Cardiovascular Drugs Product Picture
    Figure 2. Global Cardiovascular Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 3. Global Cardiovascular Drugs Market Share by Type in 2022 & 2029
    Figure 4. Renin-Angiotensin System Blockers Product Picture
    Figure 5. Beta Blockers Product Picture
    Figure 6. Diuretics Product Picture
    Figure 7. Anti-Clotting Agents Product Picture
    Figure 8. Antihyperlipidemic Product Picture
    Figure 9. Global Cardiovascular Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 10. Global Cardiovascular Drugs Market Share by Application in 2022 & 2029
    Figure 11. Hypertension
    Figure 12. Hyperlipidemia
    Figure 13. Cardiovascular Drugs Report Years Considered
    Figure 14. Global Cardiovascular Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 15. Global Cardiovascular Drugs Revenue 2018-2029 (US$ Million)
    Figure 16. Global Cardiovascular Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
    Figure 17. Global Cardiovascular Drugs Revenue Market Share by Region (2018-2029)
    Figure 18. Global Cardiovascular Drugs Sales 2018-2029 ((K Units)
    Figure 19. Global Cardiovascular Drugs Sales Market Share by Region (2018-2029)
    Figure 20. US & Canada Cardiovascular Drugs Sales YoY (2018-2029) & (K Units)
    Figure 21. US & Canada Cardiovascular Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 22. Europe Cardiovascular Drugs Sales YoY (2018-2029) & (K Units)
    Figure 23. Europe Cardiovascular Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 24. China Cardiovascular Drugs Sales YoY (2018-2029) & (K Units)
    Figure 25. China Cardiovascular Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 26. Asia (excluding China) Cardiovascular Drugs Sales YoY (2018-2029) & (K Units)
    Figure 27. Asia (excluding China) Cardiovascular Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 28. Middle East, Africa and Latin America Cardiovascular Drugs Sales YoY (2018-2029) & (K Units)
    Figure 29. Middle East, Africa and Latin America Cardiovascular Drugs Revenue YoY (2018-2029) & (US$ Million)
    Figure 30. The Cardiovascular Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
    Figure 31. The Top 5 and 10 Largest Manufacturers of Cardiovascular Drugs in the World: Market Share by Cardiovascular Drugs Revenue in 2022
    Figure 32. Global Cardiovascular Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
    Figure 33. Global Cardiovascular Drugs Sales Market Share by Type (2018-2029)
    Figure 34. Global Cardiovascular Drugs Revenue Market Share by Type (2018-2029)
    Figure 35. Global Cardiovascular Drugs Sales Market Share by Application (2018-2029)
    Figure 36. Global Cardiovascular Drugs Revenue Market Share by Application (2018-2029)
    Figure 37. US & Canada Cardiovascular Drugs Sales Market Share by Type (2018-2029)
    Figure 38. US & Canada Cardiovascular Drugs Revenue Market Share by Type (2018-2029)
    Figure 39. US & Canada Cardiovascular Drugs Sales Market Share by Application (2018-2029)
    Figure 40. US & Canada Cardiovascular Drugs Revenue Market Share by Application (2018-2029)
    Figure 41. US & Canada Cardiovascular Drugs Revenue Share by Country (2018-2029)
    Figure 42. US & Canada Cardiovascular Drugs Sales Share by Country (2018-2029)
    Figure 43. U.S. Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 44. Canada Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 45. Europe Cardiovascular Drugs Sales Market Share by Type (2018-2029)
    Figure 46. Europe Cardiovascular Drugs Revenue Market Share by Type (2018-2029)
    Figure 47. Europe Cardiovascular Drugs Sales Market Share by Application (2018-2029)
    Figure 48. Europe Cardiovascular Drugs Revenue Market Share by Application (2018-2029)
    Figure 49. Europe Cardiovascular Drugs Revenue Share by Country (2018-2029)
    Figure 50. Europe Cardiovascular Drugs Sales Share by Country (2018-2029)
    Figure 51. Germany Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 52. France Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 53. U.K. Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 54. Italy Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 55. Russia Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 56. China Cardiovascular Drugs Sales Market Share by Type (2018-2029)
    Figure 57. China Cardiovascular Drugs Revenue Market Share by Type (2018-2029)
    Figure 58. China Cardiovascular Drugs Sales Market Share by Application (2018-2029)
    Figure 59. China Cardiovascular Drugs Revenue Market Share by Application (2018-2029)
    Figure 60. Asia Cardiovascular Drugs Sales Market Share by Type (2018-2029)
    Figure 61. Asia Cardiovascular Drugs Revenue Market Share by Type (2018-2029)
    Figure 62. Asia Cardiovascular Drugs Sales Market Share by Application (2018-2029)
    Figure 63. Asia Cardiovascular Drugs Revenue Market Share by Application (2018-2029)
    Figure 64. Asia Cardiovascular Drugs Revenue Share by Region (2018-2029)
    Figure 65. Asia Cardiovascular Drugs Sales Share by Region (2018-2029)
    Figure 66. Japan Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 67. South Korea Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 68. China Taiwan Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 69. Southeast Asia Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 70. India Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 71. Middle East, Africa and Latin America Cardiovascular Drugs Sales Market Share by Type (2018-2029)
    Figure 72. Middle East, Africa and Latin America Cardiovascular Drugs Revenue Market Share by Type (2018-2029)
    Figure 73. Middle East, Africa and Latin America Cardiovascular Drugs Sales Market Share by Application (2018-2029)
    Figure 74. Middle East, Africa and Latin America Cardiovascular Drugs Revenue Market Share by Application (2018-2029)
    Figure 75. Middle East, Africa and Latin America Cardiovascular Drugs Revenue Share by Country (2018-2029)
    Figure 76. Middle East, Africa and Latin America Cardiovascular Drugs Sales Share by Country (2018-2029)
    Figure 77. Brazil Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 78. Mexico Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 79. Turkey Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 80. Israel Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 81. GCC Countries Cardiovascular Drugs Revenue (2018-2029) & (US$ Million)
    Figure 82. Cardiovascular Drugs Value Chain
    Figure 83. Cardiovascular Drugs Production Process
    Figure 84. Channels of Distribution
    Figure 85. Distributors Profiles
    Figure 86. Bottom-up and Top-down Approaches for This Report
    Figure 87. Data Triangulation
    Figure 88. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Cardiac Arrest Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-23E5775
Thu Feb 08 00:00:00 UTC 2024

Add to Cart

Global Sterols Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-7Q7477
Thu Feb 08 00:00:00 UTC 2024

Add to Cart

Global Cardiac Monitoring Devices Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-17K7269
Thu Feb 08 00:00:00 UTC 2024

Add to Cart

Global Heparin Injection Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-37T7287
Wed Feb 07 00:00:00 UTC 2024

Add to Cart